{"organizations": [], "uuid": "bc044e6d2af786975318d49dbc42132c71b4cd26", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pfizers-biosimilar-retacrit-approv/brief-pfizers-biosimilar-retacrit-approved-by-u-s-fda-idUSFWN1SM1E2", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.929, "site_type": "news", "published": "2018-05-16T03:05:00.000+03:00", "replies_count": 0, "uuid": "bc044e6d2af786975318d49dbc42132c71b4cd26"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pfizers-biosimilar-retacrit-approv/brief-pfizers-biosimilar-retacrit-approved-by-u-s-fda-idUSFWN1SM1E2", "ord_in_thread": 0, "title": "BRIEF-Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA", "locations": [], "entities": {"persons": [{"name": "retacrit", "sentiment": "none"}, {"name": "vifor", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Pfizer Inc:\n* PFIZER’S BIOSIMILAR RETACRIT® (EPOETIN ALFA-EPBX) APPROVED BY U.S. FDA\n* PFIZER INC - RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT\n* PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA INC FOR COMMERCIALIZATION OF RETACRIT IN CERTAIN CHANNELS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T03:05:00.000+03:00", "crawled": "2018-05-16T18:51:09.060+03:00", "highlightTitle": ""}